Novel TGF-βinhibitors ready for prime time in onco-immunology
Year: 2016
Type: article
Abstract: Transforming Growth Factor (TGF)-β inhibitors have been in development for decades with the outmost results of being promising candidates. From the latest clinical results at the 2016 ASCO meeting converging evidences suggest that we have moved from promising to effective drug nominees.
Source: OncoImmunology
Institutions: Université Paris Diderot, Hôpital Paris Saint-Joseph
Language: English
Topic: TGF-β signaling in diseases
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,913
OpenAlex ID: W2559766398
